Investigational drug · Phase 2
PRI-002
Also called: Contraloid
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "PRI-002"
First trial start
2024
Feb 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PRI-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Alzheimer's Disease, Early Onset
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "PRI-002" as an intervention, largest first.
- Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)Pivotal-lookingCompleted
PRInnovation GmbHIndustry
NCT06182085 · 304 participants · Start Feb 15, 2024 · Primary completion Apr 15, 2026
Drug: PRI-002; Placebo · For: Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease, Early Onset
Sites: Brno, Czechia; Hradec Králové, Czechia; Pilsen, Czechia · 38 sites in all
Prof. Dr. Dieter WillboldAcademic, hospital or other
NCT03944460 · 40 participants · Start Apr 9, 2018 · Primary completion Jul 27, 2018
Drug: Contraloid · For: Alzheimer Dementia; Alzheimer Disease
Sites: Jülich, Germany
Prof. Dr. Dieter WillboldAcademic, hospital or other
NCT03955380 · 24 participants · Start Dec 12, 2018 · Primary completion Apr 3, 2019
Drug: Contraloid · For: Alzheimer Dementia; Alzheimer Disease
Sites: Jülich, Germany
Charite University, Berlin, GermanyAcademic, hospital or other
NCT04711486 · 19 participants · Start Dec 8, 2020 · Primary completion Jan 13, 2022
Drug: Contraloid acetate; Placebo · For: Mild Cognitive Impairment Due to Alzheimer's Disease
Sites: Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetic properties of the clinical drug candidate PRI-002 with regard to genotype, sex, age, dose-dependence and food effects in mice.
Camargo LC, Jonas A, Gering I, et al. · Eur J Pharm Sci 2026
- Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial.
Kutzsche J, Cosma NC, Kauselmann G, et al. · Nat Commun 2025
- Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study.
Kutzsche J, Jürgens D, Willuweit A, et al. · Alzheimers Dement (N Y) 2020
Also in development for Mild Cognitive Impairment Due to Alzheimer's Disease
- DiranersenISIS 814907, BIIB080Phase 21 trial
Biogen · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.